nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclizine—SULT1E1—Phase II conjugation—GSTA4—liver cancer	0.023	0.0257	CbGpPWpGaD
Cyclizine—SULT1E1—Phase II conjugation—GSTA2—liver cancer	0.0225	0.0251	CbGpPWpGaD
Cyclizine—SULT1E1—Phase II conjugation—GSTA1—liver cancer	0.0217	0.0242	CbGpPWpGaD
Cyclizine—SULT1E1—Phase II conjugation—NAT2—liver cancer	0.0214	0.0239	CbGpPWpGaD
Cyclizine—SULT1E1—Phase II conjugation—HPGDS—liver cancer	0.0171	0.0191	CbGpPWpGaD
Cyclizine—SULT1E1—Biological oxidations—NR1H4—liver cancer	0.015	0.0167	CbGpPWpGaD
Cyclizine—SULT1E1—Biological oxidations—GSTA3—liver cancer	0.0147	0.0165	CbGpPWpGaD
Cyclizine—SULT1E1—Metapathway biotransformation—GSTA3—liver cancer	0.0145	0.0162	CbGpPWpGaD
Cyclizine—SULT1E1—Biological oxidations—GSTA4—liver cancer	0.0135	0.0151	CbGpPWpGaD
Cyclizine—SULT1E1—Metapathway biotransformation—GSTA4—liver cancer	0.0133	0.0148	CbGpPWpGaD
Cyclizine—SULT1E1—Biological oxidations—GSTA2—liver cancer	0.0131	0.0147	CbGpPWpGaD
Cyclizine—SULT1E1—Phase II conjugation—GGT1—liver cancer	0.0128	0.0143	CbGpPWpGaD
Cyclizine—SULT1E1—Biological oxidations—GSTA1—liver cancer	0.0127	0.0142	CbGpPWpGaD
Cyclizine—SULT1E1—Biological oxidations—NAT2—liver cancer	0.0125	0.014	CbGpPWpGaD
Cyclizine—SULT1E1—Metapathway biotransformation—NAT2—liver cancer	0.0124	0.0138	CbGpPWpGaD
Cyclizine—SULT1E1—Phase II conjugation—GSTP1—liver cancer	0.0115	0.0129	CbGpPWpGaD
Cyclizine—SULT1E1—Phase II conjugation—GSTM1—liver cancer	0.0106	0.0118	CbGpPWpGaD
Cyclizine—SULT1E1—Metapathway biotransformation—GPX3—liver cancer	0.0105	0.0117	CbGpPWpGaD
Cyclizine—SULT1E1—Biological oxidations—HPGDS—liver cancer	0.01	0.0112	CbGpPWpGaD
Cyclizine—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—liver cancer	0.0094	0.0105	CbGpPWpGaD
Cyclizine—SULT1E1—Biological oxidations—CYP2E1—liver cancer	0.00817	0.00912	CbGpPWpGaD
Cyclizine—SULT1E1—Metapathway biotransformation—CYP2E1—liver cancer	0.00805	0.009	CbGpPWpGaD
Cyclizine—CYP2C9—CYP2E1 reactions—CYP2E1—liver cancer	0.00794	0.00887	CbGpPWpGaD
Cyclizine—SULT1E1—Biological oxidations—GGT1—liver cancer	0.0075	0.00837	CbGpPWpGaD
Cyclizine—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—liver cancer	0.00736	0.00822	CbGpPWpGaD
Cyclizine—SULT1E1—Biological oxidations—GSTP1—liver cancer	0.00673	0.00752	CbGpPWpGaD
Cyclizine—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—liver cancer	0.0067	0.00748	CbGpPWpGaD
Cyclizine—SULT1E1—Metapathway biotransformation—GSTP1—liver cancer	0.00664	0.00742	CbGpPWpGaD
Cyclizine—SULT1E1—Biological oxidations—GSTM1—liver cancer	0.00619	0.00691	CbGpPWpGaD
Cyclizine—SULT1E1—Metapathway biotransformation—GSTM1—liver cancer	0.0061	0.00682	CbGpPWpGaD
Cyclizine—CYP2C9—Constitutive Androstane Receptor Pathway—NR1I3—liver cancer	0.0061	0.00681	CbGpPWpGaD
Cyclizine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1H4—liver cancer	0.00591	0.0066	CbGpPWpGaD
Cyclizine—SULT1E1—Biological oxidations—CYP1A1—liver cancer	0.00587	0.00655	CbGpPWpGaD
Cyclizine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I3—liver cancer	0.00581	0.00649	CbGpPWpGaD
Cyclizine—SULT1E1—Metapathway biotransformation—CYP1A1—liver cancer	0.00579	0.00646	CbGpPWpGaD
Cyclizine—CYP2C9—Constitutive Androstane Receptor Pathway—GSTA2—liver cancer	0.00544	0.00607	CbGpPWpGaD
Cyclizine—CYP2C9—Xenobiotics—CYP2E1—liver cancer	0.00492	0.0055	CbGpPWpGaD
Cyclizine—CYP2C9—Tamoxifen metabolism—CYP2E1—liver cancer	0.00474	0.00529	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—UGDH—liver cancer	0.00439	0.0049	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—EPT1—liver cancer	0.00413	0.00461	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—TAT—liver cancer	0.00391	0.00437	CbGpPWpGaD
Cyclizine—Hepatic function abnormal—Sorafenib—liver cancer	0.00388	0.0402	CcSEcCtD
Cyclizine—CYP2C9—Cytochrome P450 - arranged by substrate type—NR1H4—liver cancer	0.00375	0.00419	CbGpPWpGaD
Cyclizine—CYP2C9—Xenobiotics—CYP1A1—liver cancer	0.00354	0.00395	CbGpPWpGaD
Cyclizine—CYP2C9—Tamoxifen metabolism—CYP1A1—liver cancer	0.0034	0.0038	CbGpPWpGaD
Cyclizine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—liver cancer	0.00322	0.0036	CbGpPWpGaD
Cyclizine—CYP2C9—Phase 1 - Functionalization of compounds—NR1H4—liver cancer	0.00304	0.0034	CbGpPWpGaD
Cyclizine—CYP2C9—Arachidonic acid metabolism—HPGDS—liver cancer	0.0029	0.00324	CbGpPWpGaD
Cyclizine—CYP2C9—Biological oxidations—UGDH—liver cancer	0.00277	0.00309	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—CPT1B—liver cancer	0.00266	0.00297	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—GLUL—liver cancer	0.00266	0.00297	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—NR1H4—liver cancer	0.00256	0.00286	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—GSTA3—liver cancer	0.00252	0.00282	CbGpPWpGaD
Cyclizine—Hepatobiliary disease—Sorafenib—liver cancer	0.00247	0.0256	CcSEcCtD
Cyclizine—Blister—Epirubicin—liver cancer	0.00239	0.0248	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—GSTA4—liver cancer	0.0023	0.00257	CbGpPWpGaD
Cyclizine—Connective tissue disorder—Sorafenib—liver cancer	0.0023	0.0239	CcSEcCtD
Cyclizine—HRH1—IL-4 Signaling Pathway—MAPK14—liver cancer	0.00229	0.00256	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—GSTA2—liver cancer	0.00225	0.00251	CbGpPWpGaD
Cyclizine—Blister—Doxorubicin—liver cancer	0.00222	0.0229	CcSEcCtD
Cyclizine—CYP2C9—Arachidonic acid metabolism—GGT1—liver cancer	0.00217	0.00243	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—GSTA1—liver cancer	0.00217	0.00242	CbGpPWpGaD
Cyclizine—HRH1—G alpha (q) signalling events—TRIO—liver cancer	0.00215	0.0024	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—NAT2—liver cancer	0.00214	0.00239	CbGpPWpGaD
Cyclizine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—liver cancer	0.00212	0.00236	CbGpPWpGaD
Cyclizine—Mental disorder—Sorafenib—liver cancer	0.00205	0.0213	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—ALDOB—liver cancer	0.00205	0.00229	CbGpPWpGaD
Cyclizine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2E1—liver cancer	0.00204	0.00228	CbGpPWpGaD
Cyclizine—Erythema—Sorafenib—liver cancer	0.00204	0.0211	CcSEcCtD
Cyclizine—CYP2C9—Oxidation by Cytochrome P450—CYP2E1—liver cancer	0.00202	0.00225	CbGpPWpGaD
Cyclizine—Bifonazole—CYP2E1—liver cancer	0.002	0.245	CrCbGaD
Cyclizine—Jaundice cholestatic—Epirubicin—liver cancer	0.00196	0.0203	CcSEcCtD
Cyclizine—Muscle spasms—Sorafenib—liver cancer	0.00196	0.0203	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—CRABP1—liver cancer	0.00196	0.00219	CbGpPWpGaD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—TRIO—liver cancer	0.00192	0.00214	CbGpPWpGaD
Cyclizine—HRH1—IL-4 Signaling Pathway—PIK3CD—liver cancer	0.00187	0.00209	CbGpPWpGaD
Cyclizine—Angioedema—Sorafenib—liver cancer	0.00187	0.0193	CcSEcCtD
Cyclizine—Dyskinesia—Epirubicin—liver cancer	0.00184	0.019	CcSEcCtD
Cyclizine—Jaundice cholestatic—Doxorubicin—liver cancer	0.00182	0.0188	CcSEcCtD
Cyclizine—Hypertension—Sorafenib—liver cancer	0.00176	0.0183	CcSEcCtD
Cyclizine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—liver cancer	0.00175	0.00195	CbGpPWpGaD
Cyclizine—Injection site reaction—Epirubicin—liver cancer	0.00172	0.0178	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—HPGDS—liver cancer	0.00171	0.00191	CbGpPWpGaD
Cyclizine—CYP2C9—Arachidonic acid metabolism—CYP1A1—liver cancer	0.0017	0.0019	CbGpPWpGaD
Cyclizine—Dyskinesia—Doxorubicin—liver cancer	0.0017	0.0176	CcSEcCtD
Cyclizine—Anaphylactic shock—Sorafenib—liver cancer	0.00167	0.0173	CcSEcCtD
Cyclizine—CYP2C9—Phase 1 - Functionalization of compounds—CYP2E1—liver cancer	0.00166	0.00185	CbGpPWpGaD
Cyclizine—Nervous system disorder—Sorafenib—liver cancer	0.00163	0.0169	CcSEcCtD
Cyclizine—Skin disorder—Sorafenib—liver cancer	0.00162	0.0168	CcSEcCtD
Cyclizine—CYP2C9—Biological oxidations—NR1H4—liver cancer	0.00162	0.00181	CbGpPWpGaD
Cyclizine—HRH1—GPCRs, Class A Rhodopsin-like—CCR4—liver cancer	0.00159	0.00178	CbGpPWpGaD
Cyclizine—CYP2C9—Biological oxidations—GSTA3—liver cancer	0.00159	0.00177	CbGpPWpGaD
Cyclizine—Injection site reaction—Doxorubicin—liver cancer	0.00159	0.0164	CcSEcCtD
Cyclizine—Flunarizine—CYP1A1—liver cancer	0.00158	0.194	CrCbGaD
Cyclizine—CYP2C9—Metapathway biotransformation—GSTA3—liver cancer	0.00157	0.00175	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—PSMA4—liver cancer	0.00153	0.00171	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—PSMD10—liver cancer	0.00153	0.00171	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—GOT2—liver cancer	0.00149	0.00166	CbGpPWpGaD
Cyclizine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—liver cancer	0.00147	0.00164	CbGpPWpGaD
Cyclizine—CYP2C9—Biological oxidations—GSTA4—liver cancer	0.00145	0.00162	CbGpPWpGaD
Cyclizine—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—liver cancer	0.00145	0.00162	CbGpPWpGaD
Cyclizine—Thrombophlebitis—Epirubicin—liver cancer	0.00145	0.015	CcSEcCtD
Cyclizine—Hepatic function abnormal—Epirubicin—liver cancer	0.00143	0.0148	CcSEcCtD
Cyclizine—CYP2C9—Metapathway biotransformation—GSTA4—liver cancer	0.00143	0.0016	CbGpPWpGaD
Cyclizine—Constipation—Sorafenib—liver cancer	0.00143	0.0148	CcSEcCtD
Cyclizine—Pain—Sorafenib—liver cancer	0.00143	0.0148	CcSEcCtD
Cyclizine—CYP2C9—Biological oxidations—GSTA2—liver cancer	0.00142	0.00158	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—CYP2E1—liver cancer	0.0014	0.00156	CbGpPWpGaD
Cyclizine—CYP2C9—Biological oxidations—GSTA1—liver cancer	0.00137	0.00153	CbGpPWpGaD
Cyclizine—HRH1—Class A/1 (Rhodopsin-like receptors)—CCR4—liver cancer	0.00136	0.00152	CbGpPWpGaD
Cyclizine—CYP2C9—Biological oxidations—NAT2—liver cancer	0.00135	0.00151	CbGpPWpGaD
Cyclizine—Thrombophlebitis—Doxorubicin—liver cancer	0.00134	0.0139	CcSEcCtD
Cyclizine—CYP2C9—Metapathway biotransformation—NAT2—liver cancer	0.00133	0.00149	CbGpPWpGaD
Cyclizine—Hepatic function abnormal—Doxorubicin—liver cancer	0.00133	0.0137	CcSEcCtD
Cyclizine—Urticaria—Sorafenib—liver cancer	0.00132	0.0137	CcSEcCtD
Cyclizine—Dermatitis bullous—Epirubicin—liver cancer	0.00131	0.0136	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—CYCS—liver cancer	0.00131	0.00146	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—GOT1—liver cancer	0.00128	0.00143	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—GGT1—liver cancer	0.00128	0.00143	CbGpPWpGaD
Cyclizine—HRH1—IL-4 Signaling Pathway—STAT3—liver cancer	0.00126	0.00141	CbGpPWpGaD
Cyclizine—Cinnarizine—CYP1A1—liver cancer	0.00125	0.154	CrCbGaD
Cyclizine—Hypersensitivity—Sorafenib—liver cancer	0.00123	0.0127	CcSEcCtD
Cyclizine—Dermatitis bullous—Doxorubicin—liver cancer	0.00121	0.0126	CcSEcCtD
Cyclizine—Asthenia—Sorafenib—liver cancer	0.0012	0.0124	CcSEcCtD
Cyclizine—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	0.00119	0.00133	CbGpPWpGaD
Cyclizine—HRH1—G alpha (q) signalling events—PRKCE—liver cancer	0.00118	0.00132	CbGpPWpGaD
Cyclizine—Pruritus—Sorafenib—liver cancer	0.00118	0.0122	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—GSTP1—liver cancer	0.00115	0.00129	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—HMOX1—liver cancer	0.00114	0.00127	CbGpPWpGaD
Cyclizine—CYP2C9—Metapathway biotransformation—GPX3—liver cancer	0.00113	0.00127	CbGpPWpGaD
Cyclizine—Dizziness—Sorafenib—liver cancer	0.0011	0.0114	CcSEcCtD
Cyclizine—CYP2C9—Biological oxidations—HPGDS—liver cancer	0.00108	0.00121	CbGpPWpGaD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—PRKCE—liver cancer	0.00106	0.00118	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—GSTM1—liver cancer	0.00106	0.00118	CbGpPWpGaD
Cyclizine—Headache—Sorafenib—liver cancer	0.00104	0.0108	CcSEcCtD
Cyclizine—HRH1—GPCR ligand binding—CCR4—liver cancer	0.00104	0.00116	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—CYP1A1—liver cancer	0.001	0.00112	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—EPT1—liver cancer	0.000999	0.00112	CbGpPWpGaD
Cyclizine—HRH1—IL-4 Signaling Pathway—PIK3CA—liver cancer	0.000993	0.00111	CbGpPWpGaD
Cyclizine—Phenprocoumon—ALB—liver cancer	0.000992	0.122	CrCbGaD
Cyclizine—Drowsiness—Epirubicin—liver cancer	0.000966	0.01	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—MTHFR—liver cancer	0.000935	0.00104	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—PPARA—liver cancer	0.000918	0.00102	CbGpPWpGaD
Cyclizine—Hepatobiliary disease—Epirubicin—liver cancer	0.000913	0.00946	CcSEcCtD
Cyclizine—Agranulocytosis—Epirubicin—liver cancer	0.000901	0.00933	CcSEcCtD
Cyclizine—Drowsiness—Doxorubicin—liver cancer	0.000893	0.00925	CcSEcCtD
Cyclizine—CYP2C9—Biological oxidations—CYP2E1—liver cancer	0.00088	0.000983	CbGpPWpGaD
Cyclizine—CYP2C9—Metapathway biotransformation—CYP2E1—liver cancer	0.000868	0.00097	CbGpPWpGaD
Cyclizine—Hepatitis—Epirubicin—liver cancer	0.000867	0.00898	CcSEcCtD
Cyclizine—Orphenadrine—CYP2E1—liver cancer	0.000862	0.106	CrCbGaD
Cyclizine—Connective tissue disorder—Epirubicin—liver cancer	0.000852	0.00882	CcSEcCtD
Cyclizine—Hepatobiliary disease—Doxorubicin—liver cancer	0.000845	0.00875	CcSEcCtD
Cyclizine—Agranulocytosis—Doxorubicin—liver cancer	0.000834	0.00863	CcSEcCtD
Cyclizine—HRH1—G alpha (q) signalling events—F2—liver cancer	0.000822	0.000918	CbGpPWpGaD
Cyclizine—HRH1—IL-4 Signaling Pathway—AKT1—liver cancer	0.000811	0.000906	CbGpPWpGaD
Cyclizine—Eye disorder—Epirubicin—liver cancer	0.00081	0.00839	CcSEcCtD
Cyclizine—CYP2C9—Biological oxidations—GGT1—liver cancer	0.000808	0.000903	CbGpPWpGaD
Cyclizine—Hepatitis—Doxorubicin—liver cancer	0.000802	0.0083	CcSEcCtD
Cyclizine—HRH1—Signaling Pathways—CHN2—liver cancer	0.00079	0.000882	CbGpPWpGaD
Cyclizine—Connective tissue disorder—Doxorubicin—liver cancer	0.000788	0.00816	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—PIK3CG—liver cancer	0.000786	0.000878	CbGpPWpGaD
Cyclizine—Chills—Epirubicin—liver cancer	0.000778	0.00805	CcSEcCtD
Cyclizine—Mental disorder—Epirubicin—liver cancer	0.000759	0.00786	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—PPARG—liver cancer	0.000758	0.000847	CbGpPWpGaD
Cyclizine—Erythema—Epirubicin—liver cancer	0.000755	0.00781	CcSEcCtD
Cyclizine—Eye disorder—Doxorubicin—liver cancer	0.00075	0.00776	CcSEcCtD
Cyclizine—Tension—Epirubicin—liver cancer	0.00074	0.00767	CcSEcCtD
Cyclizine—Clozapine—CYP2E1—liver cancer	0.000736	0.0903	CrCbGaD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—F2—liver cancer	0.000735	0.000821	CbGpPWpGaD
Cyclizine—Nervousness—Epirubicin—liver cancer	0.000733	0.00759	CcSEcCtD
Cyclizine—CYP2C9—Biological oxidations—GSTP1—liver cancer	0.000726	0.000811	CbGpPWpGaD
Cyclizine—Clozapine—CYP1A1—liver cancer	0.000726	0.0891	CrCbGaD
Cyclizine—Muscle spasms—Epirubicin—liver cancer	0.000725	0.00751	CcSEcCtD
Cyclizine—HRH1—Signaling Pathways—IFT88—liver cancer	0.000722	0.000807	CbGpPWpGaD
Cyclizine—Chills—Doxorubicin—liver cancer	0.00072	0.00745	CcSEcCtD
Cyclizine—CYP2C9—Metapathway biotransformation—GSTP1—liver cancer	0.000716	0.0008	CbGpPWpGaD
Cyclizine—Vision blurred—Epirubicin—liver cancer	0.000711	0.00736	CcSEcCtD
Cyclizine—Mental disorder—Doxorubicin—liver cancer	0.000703	0.00728	CcSEcCtD
Cyclizine—Erythema—Doxorubicin—liver cancer	0.000698	0.00723	CcSEcCtD
Cyclizine—Agitation—Epirubicin—liver cancer	0.000693	0.00718	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—PIK3CD—liver cancer	0.000691	0.000772	CbGpPWpGaD
Cyclizine—Tension—Doxorubicin—liver cancer	0.000685	0.00709	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—ALB—liver cancer	0.000682	0.000762	CbGpPWpGaD
Cyclizine—Nervousness—Doxorubicin—liver cancer	0.000678	0.00702	CcSEcCtD
Cyclizine—Muscle spasms—Doxorubicin—liver cancer	0.000671	0.00695	CcSEcCtD
Cyclizine—CYP2C9—Biological oxidations—GSTM1—liver cancer	0.000667	0.000745	CbGpPWpGaD
Cyclizine—CYP2C9—Metapathway biotransformation—GSTM1—liver cancer	0.000658	0.000735	CbGpPWpGaD
Cyclizine—Vision blurred—Doxorubicin—liver cancer	0.000658	0.00681	CcSEcCtD
Cyclizine—Convulsion—Epirubicin—liver cancer	0.000654	0.00677	CcSEcCtD
Cyclizine—Hypertension—Epirubicin—liver cancer	0.000651	0.00675	CcSEcCtD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—CPT1B—liver cancer	0.000644	0.000719	CbGpPWpGaD
Cyclizine—Agitation—Doxorubicin—liver cancer	0.000642	0.00664	CcSEcCtD
Cyclizine—CYP2C9—Biological oxidations—CYP1A1—liver cancer	0.000633	0.000707	CbGpPWpGaD
Cyclizine—CYP2C9—Metapathway biotransformation—CYP1A1—liver cancer	0.000624	0.000697	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—NR1H4—liver cancer	0.000621	0.000693	CbGpPWpGaD
Cyclizine—Anaphylactic shock—Epirubicin—liver cancer	0.000616	0.00638	CcSEcCtD
Cyclizine—HRH1—GPCR downstream signaling—TRIO—liver cancer	0.000611	0.000683	CbGpPWpGaD
Cyclizine—Convulsion—Doxorubicin—liver cancer	0.000605	0.00626	CcSEcCtD
Cyclizine—Nervous system disorder—Epirubicin—liver cancer	0.000604	0.00625	CcSEcCtD
Cyclizine—Hypertension—Doxorubicin—liver cancer	0.000603	0.00624	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—PIK3CB—liver cancer	0.000602	0.000673	CbGpPWpGaD
Cyclizine—Tachycardia—Epirubicin—liver cancer	0.000601	0.00622	CcSEcCtD
Cyclizine—Skin disorder—Epirubicin—liver cancer	0.000598	0.00619	CcSEcCtD
Cyclizine—HRH1—GPCR downstream signaling—CCR4—liver cancer	0.000586	0.000655	CbGpPWpGaD
Cyclizine—Hypotension—Epirubicin—liver cancer	0.000575	0.00596	CcSEcCtD
Cyclizine—Anaphylactic shock—Doxorubicin—liver cancer	0.00057	0.0059	CcSEcCtD
Cyclizine—Nervous system disorder—Doxorubicin—liver cancer	0.000559	0.00579	CcSEcCtD
Cyclizine—Insomnia—Epirubicin—liver cancer	0.000557	0.00577	CcSEcCtD
Cyclizine—Tachycardia—Doxorubicin—liver cancer	0.000556	0.00576	CcSEcCtD
Cyclizine—HRH1—Signaling by GPCR—TRIO—liver cancer	0.000555	0.00062	CbGpPWpGaD
Cyclizine—Skin disorder—Doxorubicin—liver cancer	0.000553	0.00573	CcSEcCtD
Cyclizine—Paraesthesia—Epirubicin—liver cancer	0.000553	0.00573	CcSEcCtD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—liver cancer	0.000552	0.000617	CbGpPWpGaD
Cyclizine—Somnolence—Epirubicin—liver cancer	0.000547	0.00567	CcSEcCtD
Cyclizine—HRH1—Class A/1 (Rhodopsin-like receptors)—F2—liver cancer	0.000544	0.000608	CbGpPWpGaD
Cyclizine—Hypotension—Doxorubicin—liver cancer	0.000532	0.00551	CcSEcCtD
Cyclizine—HRH1—Signaling by GPCR—CCR4—liver cancer	0.000532	0.000595	CbGpPWpGaD
Cyclizine—Constipation—Epirubicin—liver cancer	0.000527	0.00545	CcSEcCtD
Cyclizine—Pain—Epirubicin—liver cancer	0.000527	0.00545	CcSEcCtD
Cyclizine—Insomnia—Doxorubicin—liver cancer	0.000515	0.00534	CcSEcCtD
Cyclizine—Paraesthesia—Doxorubicin—liver cancer	0.000512	0.0053	CcSEcCtD
Cyclizine—Somnolence—Doxorubicin—liver cancer	0.000507	0.00525	CcSEcCtD
Cyclizine—Urticaria—Epirubicin—liver cancer	0.000489	0.00507	CcSEcCtD
Cyclizine—Constipation—Doxorubicin—liver cancer	0.000487	0.00505	CcSEcCtD
Cyclizine—Pain—Doxorubicin—liver cancer	0.000487	0.00505	CcSEcCtD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—liver cancer	0.000474	0.00053	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—UGDH—liver cancer	0.000473	0.000528	CbGpPWpGaD
Cyclizine—Hypersensitivity—Epirubicin—liver cancer	0.000454	0.0047	CcSEcCtD
Cyclizine—Urticaria—Doxorubicin—liver cancer	0.000453	0.00469	CcSEcCtD
Cyclizine—CYP2C9—Metabolism—EPT1—liver cancer	0.000445	0.000497	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—SHC3—liver cancer	0.000443	0.000495	CbGpPWpGaD
Cyclizine—Asthenia—Epirubicin—liver cancer	0.000442	0.00458	CcSEcCtD
Cyclizine—Pruritus—Epirubicin—liver cancer	0.000436	0.00451	CcSEcCtD
Cyclizine—CYP2C9—Metabolism—TAT—liver cancer	0.000422	0.000471	CbGpPWpGaD
Cyclizine—Hypersensitivity—Doxorubicin—liver cancer	0.00042	0.00435	CcSEcCtD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—liver cancer	0.000415	0.000463	CbGpPWpGaD
Cyclizine—HRH1—GPCR ligand binding—F2—liver cancer	0.000415	0.000463	CbGpPWpGaD
Cyclizine—Asthenia—Doxorubicin—liver cancer	0.000409	0.00423	CcSEcCtD
Cyclizine—Dizziness—Epirubicin—liver cancer	0.000407	0.00422	CcSEcCtD
Cyclizine—Pruritus—Doxorubicin—liver cancer	0.000403	0.00417	CcSEcCtD
Cyclizine—Headache—Epirubicin—liver cancer	0.000386	0.00399	CcSEcCtD
Cyclizine—Dizziness—Doxorubicin—liver cancer	0.000377	0.0039	CcSEcCtD
Cyclizine—HRH1—G alpha (q) signalling events—PIK3CA—liver cancer	0.000368	0.00041	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—PIK3CA—liver cancer	0.000367	0.00041	CbGpPWpGaD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—liver cancer	0.000358	0.0004	CbGpPWpGaD
Cyclizine—Headache—Doxorubicin—liver cancer	0.000357	0.0037	CcSEcCtD
Cyclizine—HRH1—Signaling Pathways—FST—liver cancer	0.000344	0.000384	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—PRKCE—liver cancer	0.000338	0.000377	CbGpPWpGaD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—liver cancer	0.000329	0.000367	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—TRIO—liver cancer	0.000328	0.000366	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CCR4—liver cancer	0.000314	0.000351	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—GGT1—liver cancer	0.00031	0.000347	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—PRKCE—liver cancer	0.000307	0.000342	CbGpPWpGaD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—liver cancer	0.000304	0.00034	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—AKT1—liver cancer	0.0003	0.000335	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—CSF2—liver cancer	0.000299	0.000334	CbGpPWpGaD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—liver cancer	0.000291	0.000325	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CPT1B—liver cancer	0.000287	0.00032	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GLUL—liver cancer	0.000287	0.00032	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—NR1H4—liver cancer	0.000276	0.000309	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GSTA3—liver cancer	0.000272	0.000304	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—CSF2—liver cancer	0.000271	0.000303	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—ADAM17—liver cancer	0.000249	0.000278	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GSTA4—liver cancer	0.000249	0.000278	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	0.000243	0.000271	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GSTA2—liver cancer	0.000242	0.000271	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—F2—liver cancer	0.000234	0.000262	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PSMA4—liver cancer	0.000234	0.000261	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PSMD10—liver cancer	0.000234	0.000261	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GSTA1—liver cancer	0.000234	0.000261	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—NAT2—liver cancer	0.000231	0.000258	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—PIK3CG—liver cancer	0.000224	0.00025	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PPARA—liver cancer	0.000222	0.000248	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ALDOB—liver cancer	0.000222	0.000247	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—F2—liver cancer	0.000213	0.000238	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CRABP1—liver cancer	0.000211	0.000236	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—PIK3CG—liver cancer	0.000204	0.000227	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—PIK3CD—liver cancer	0.000197	0.00022	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	0.00019	0.000213	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—HPGDS—liver cancer	0.000185	0.000206	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—liver cancer	0.000184	0.000205	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PRKCE—liver cancer	0.000181	0.000202	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—PIK3CD—liver cancer	0.000179	0.0002	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—PIK3CB—liver cancer	0.000172	0.000192	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—IGF2—liver cancer	0.000172	0.000192	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	0.000167	0.000187	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—liver cancer	0.000165	0.000184	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PSMA4—liver cancer	0.000165	0.000184	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PSMD10—liver cancer	0.000165	0.000184	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CSF2—liver cancer	0.00016	0.000179	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GOT2—liver cancer	0.00016	0.000179	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—RAF1—liver cancer	0.00016	0.000179	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—H2AFX—liver cancer	0.000158	0.000176	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—IL2—liver cancer	0.000158	0.000176	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—PIK3CB—liver cancer	0.000156	0.000174	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CYP2E1—liver cancer	0.000151	0.000168	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	0.000146	0.000163	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—IL2—liver cancer	0.000143	0.00016	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—TERT—liver cancer	0.000143	0.000159	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CYCS—liver cancer	0.000141	0.000157	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GOT1—liver cancer	0.000138	0.000154	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GGT1—liver cancer	0.000138	0.000154	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—KDR—liver cancer	0.000131	0.000146	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—MAPK14—liver cancer	0.00013	0.000145	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—ESR1—liver cancer	0.000127	0.000142	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—F2—liver cancer	0.000126	0.00014	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GSTP1—liver cancer	0.000124	0.000139	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—HMOX1—liver cancer	0.000122	0.000137	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—APC—liver cancer	0.00012	0.000134	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PIK3CG—liver cancer	0.00012	0.000134	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GSTM1—liver cancer	0.000114	0.000127	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—BRAF—liver cancer	0.000113	0.000126	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CYP1A1—liver cancer	0.000108	0.000121	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PIK3CD—liver cancer	0.000106	0.000118	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—PIK3CA—liver cancer	0.000105	0.000117	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—SERPINE1—liver cancer	0.000105	0.000117	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—KRAS—liver cancer	0.000104	0.000116	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—MTHFR—liver cancer	0.000101	0.000113	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PPARA—liver cancer	9.89e-05	0.000111	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—PIK3CA—liver cancer	9.51e-05	0.000106	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—RAF1—liver cancer	9.44e-05	0.000105	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PIK3CB—liver cancer	9.22e-05	0.000103	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—MTOR—liver cancer	9.22e-05	0.000103	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	8.89e-05	9.93e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—HRAS—liver cancer	8.8e-05	9.83e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CDKN1B—liver cancer	8.65e-05	9.66e-05	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—AKT1—liver cancer	8.56e-05	9.56e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CASP3—liver cancer	8.48e-05	9.47e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PIK3CG—liver cancer	8.47e-05	9.46e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—IL2—liver cancer	8.46e-05	9.46e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—IL6—liver cancer	8.42e-05	9.41e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CCND1—liver cancer	8.25e-05	9.22e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—JUN—liver cancer	8.23e-05	9.2e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PPARG—liver cancer	8.18e-05	9.13e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CTNNB1—liver cancer	8.17e-05	9.13e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—MMP9—liver cancer	8.01e-05	8.95e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CDKN1A—liver cancer	7.98e-05	8.92e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—MAPK8—liver cancer	7.79e-05	8.7e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—AKT1—liver cancer	7.77e-05	8.68e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PIK3CD—liver cancer	7.45e-05	8.32e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ALB—liver cancer	7.35e-05	8.21e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—VEGFA—liver cancer	7.19e-05	8.04e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—STAT3—liver cancer	7.12e-05	7.96e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—MYC—liver cancer	6.62e-05	7.39e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—TGFB1—liver cancer	6.6e-05	7.38e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PIK3CB—liver cancer	6.49e-05	7.25e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—KRAS—liver cancer	6.12e-05	6.83e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PIK3CA—liver cancer	5.62e-05	6.28e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—TP53—liver cancer	5.44e-05	6.07e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—HRAS—liver cancer	5.2e-05	5.81e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—IL6—liver cancer	4.98e-05	5.56e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—AKT1—liver cancer	4.59e-05	5.13e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PIK3CA—liver cancer	3.96e-05	4.42e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—AKT1—liver cancer	3.23e-05	3.61e-05	CbGpPWpGaD
